Articles published by Thubrikar Aortic Valve, Inc.

Thubrikar Aortic Valve partners with MAC’s MEDICAL Group and expands the TAVI-1 CE Mark trial of the Optimum TAVI System™

June 26, 2026

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Thubrikar Aortic Valve to Present Clinical Success of the Optimum TAVI System™ in 12 Patients at TCT 2024

October 01, 2024

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Thubrikar Aortic Valve Announces Clinical Success of the New Precision 2™ Delivery Catheter

May 06, 2024

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Thubrikar Aortic Valve Announces Authorization to Expand the TAVI-1 CE Mark Trial with the Precision 2™ Delivery Catheter

December 15, 2023

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Thubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study With Novel Optimum TAV™ at EuroPCR 2023

May 02, 2023

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Thubrikar Aortic Valve completes initial CE Mark-enabling TAVI-1 Study

October 21, 2022

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Thubrikar Aortic Valve announces initial 30-day outcomes of CE Mark-enabling TAVI-1 Study

August 02, 2022

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Thubrikar Aortic Valve Announces Authorization to Initiate Patient Implants Toward CE Mark Approval of Optimum TAV™, and Development of Its Novel Precision 2™ Delivery Catheter

December 17, 2021

From Thubrikar Aortic Valve, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.